Dihydrothiazine prodrugs of thiazolium agents
View Patent ↗Provided are compounds of the formula (and pharmaceutically acceptable salts thereof): wherein: R is hydrogen, methyl, hydroxymethyl or α-hydroxyethyl; R 1 and R 2 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin- 1 -ylalkyl; and Y is selected from the group consisting of C 1 -C 6 alkyl, substituted and unsubstituted aryl; with the provisos that: (a) if Y is aryl, then at least one of R 1 and R 2 is other than hydrogen, and (b) if R 2 is hydrogen R 1 is other than methyl. Also provided are pharmaceutical compositions containing the compounds, and methods for the preparation of the compounds. The compounds are useful, among other things, as prodrugs which can be converted under acidic conditions to thiazolium agents. The compounds can be administered to mammals, including humans, for treatment of various indications.
1. A compound of the formula:
wherein:
R is hydrogen, methyl, hydroxymethyl or α-hydroxyethyl;
R 1 and R 2 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl; and
Y is selected from the group consisting of C 1 -C 6 alkyl, and substituted and unsubstituted aryl, wherein substituted aryl is substituted with one to three substituents selected from amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, cyano, nitro, C 1 -C 6 mono, di- or trifluoroalkyl, nitro, fluoro, chioro and bromo;
with the provisos that:
(a) if Y is aryl, then at least one of R 1 and R 2 is other than hydrogen, and
(b) if R 2 is other than methyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 1 and R 2 are independently selected from C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkenyl, C 1 C 6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl.
3. The compound of claim 2 , wherein R is hydrogen, hydroxymethyl or α-hydroxyethyl.
4. The compound of claim 1 , wherein at least one of R 1 and R 2 is C 1 -C 6 alkyl.
5. The compound of claim 4 , wherein at least one of R 1 and R 2 is methyl.
6. The compound of claim 4 , wherein Y is selected from the group consisting of substituted and unsubstituted phenyl.
7. The compound of claim 6 , wherein Y is unsubstituted phenyl.
8. The compound of claim 7 ; 2-hydroxy-5,6-dimethyl-2-phenyl-2,3-dihydro-(1, 4)-thiazine-4-carbaldehyde.
9. The compound of claim 7 , wherein R is α-hydroxyethyl and R 1 and R 2 are both methyl.
10. The compound of claim 1 , wherein at least one of R 1 and R 2 is C 1 -C 6 hydroxyalkyl.
11. The compound of claim 10 , wherein at least one of R 1 and R 2 is 2-hydroxyethyl.
12. The compound of claim 1 , wherein Y is substituted aryl.
13. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula:
wherein:
R is hydrogen, methyl, hydroxymethyl or α-hydroxyethyl;
R 1 and R 2 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl; and
Y is selected from the group consisting of C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, cyano, nitro, C 1 -C 6 mono, di- or trifluoroalkyl, nitro, fluoro, chloro and bromo;
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , wherein at least one of R 1 and R 2 is other than hydrogen, and if R 2 is hydrogen R 1 is other than methyl.
15. The pharmaceutical composition of claim 14 , wherein R is hydrogen, R 1 and R 2 are both methyl and Y is unsubstituted phenyl.
16. The pharmaceutical composition of claim 14 , wherein R is α-hydroxyethyl, R 1 and R 2 are both methyl and Y is unsubstituted phenyl.
17. A method for preparing a compound of the formula:
comprising:
treating a thiazolium compound of the formula:
wherein:
R is hydrogen, methyl, hydroxymethyl or α-hydroxyethyl;
R 1 and R 2 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin- 1 -ylalkyl; and
Y is selected from the group consisting of a substituted and unsubstituted aryl, wherein substituted aryl is substituted with one to three substituents selected from amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 alkyl, cyano, nitro, C 1 -C 6 mono, di- or trifluoroalkyl, nitro, fluoro, chioro and bromo; and X- is an anion;
with the provisos that:
(a) if Y is aryl, then at least one of R 1 and R 2 is other than hydrogen, and
(b) if R 2 is hydrogen R 1 is other than methyl; with an aqueous alkaline solution to afford the compound of the formula I.
18. The method of claim 17 , wherein the pH of the aqueous alkaline solution is at least 8.
19. The method of claim 18 , wherein the pH of the aqueous alkaline solution is between 9 and 11.
20. The method of claim 17 , wherein R is hydrogen, R 1 and R 2 are both methyl and Y is unsubstituted phenyl.
21. A method of treating a mammal having an indication, wherein the indication is selected from hypertension, reduced vascular compliance, diastolic dysfunction, heart failure, comprising: administering an effective amount of the compound of claim 1 to the mammal.
22. The method of claim 21 , wherein the indication is hypertension.
23. The method of claim 22 , wherein the hypertension is isolated systolic hypertension.
24. The method of claim 22 , wherein the hypertension is systolic hypertension.
25. The method of claim 21 , wherein the indication is reduced vascular compliance.
26. The method of claim 21 , wherein the indication is diastolic dysfunction.
27. The method of claim 21 , wherein the indication is heart failure.
28. The method of claim 21 , wherein the indication is diastolic heart failure.